The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I have spoken at length to VIY and another majorR selling point is the time frame - 2 days as opposed to 14-16 days. Also, its Downs at present but in the future the model and technology can be used for a myriad of other health related tests.
they are not targeting the US.
Premaitha is the first company to have this in Europe, but despite developing test, my understand is that there is no proprietary IPR on it. However they will be first to market and will sell it for around £200 to the 600 odd UK labs initially capable of processing it, who will in turn sell it on for and £350 at the top end. I believe but don't quote me on it, that the test costs around £100 to produce. So it's slightly cheaper than the current £400 test that also involves sending abroad. Obviously there is sufficient margin in there for Uk labs to reduce costs if they want. The real test to compare it with right now though is the amniocentesis itself which is the only other local alternative to the Premaitha test which costs a minimum of £800. As you rightly say there is a basic screening test right now of ultrasound and hormonal analysis. This will not replace the hormonal analysis, but I do see it in time and with economy of scale being the one and only early stage pre-natal blood test. Why screen to see what yours odds of an issue are when you can just screen for genetic markers with almost complete accuracy. The hormone markers are known to be nothing more than very general indicators anyway and are often wrong in that they highlight cases for concern when there is none, and miss the many pregnancies that go on to have children with birth defects not previously known. That is not to say that the current 700,000 born with Downs for example are as a result of tests going wrong, there are of course parents who decide to not have the test as it would make no difference to their personal decision anyway, this is not an ethical question; just changing the quality and invasive ness of what's already available. With the current normal screening, a 1 in 20,000 chance or greater is considered acceptable risk for Downs for example. 1 in 1,000 is very high risk. This puts into perspective both our kids having 1 in 16 results which was off the scale and unheard of, almost a given they had Downs. And yet neither did after the awful amniocentesis. The initial screening was wildly inaccurate, and the awful invasive test not needed. I know we are here to make a return, but I note a couple of posters have personal experience of this, and it was an agonising decisions to have the procedure for us, and it felt awful watching the consultant put that needle into your wife's abdomen where your unborn baby was, praying it will be still. Sounds a bit melodramatic, but this will be fantastic. European market alone is huge and much more opportunity worldwide, no reason why the US can't come further down the line.
on your 11p as it stand right now at 0.155.
- Current cost of amniocentesis is £800 at least depending on NHS Trust - Competitive product is £400, but involves sending abroad to China to US labs. And specialist service. - Premaitha Health product costs £200 to UK labs which they hope to market to around 600 who will add margin and sell for no more than £350 top end. Has cost savings as well as patient benefits. Good stuff, note that Rupert Lywood and Charles Roberts are both personal shareholders and significant stakeholders through Zoragen Biotechnologies LLP, Animatrix Capital LLP and Loxbridge Research LLP (47.6% between those three companies and personal holdings). Basically they are pretty much all the sticky money in this venture. There is 55% do shares not in public hands and taking these investors into account that's 62.6% in total that will be in this for the long haul. Bearing in mind also people like myself partaking in fundraising that is sticky money, you can understand why it's being spoken on 10% of shares being traded here. No wonder they anticipate such a large growth in mcap along with a bright future for the products indeed.
My brokers are quite picky about what AIM shares they invest in, and they said this was one of the strongest boards they had come across and it they got no-where near their requested allocation. Adam Reynolds has described the reverse take-over as one of the best deals he has ever done. I did a fair few notes on the product a couple of weeks back, I'll dig them out for people fresh in today trying to find out more about the stock.
I'm thinking that the SP has been pushed up artificially today , because of the last day of open offer. If tomorrow it will go down to 0.13 which 70% is gonna happen in my opinion it means that the SP is manipulated.
I have noon Friday the 27th June as the last day with Hargreaves Lansdown .
This will become the hot share of 2014 - Premaitha will have so much demand for their products. NHS and private hospitals. If they can get this into the US it will explode!!!!!! DYOR x
& some good PR has pushed us up..I was unaware that the ii's had oversubscribed to the power of 4, so change of heart for me, i'm gonna e-mail bestinvest now & take up the offer after all & try to get some extra too..
Yes, definitely a fair point to say now this has been tipped! When I wrote it, it was 0.13 on the Ask and made more sense.
calculated risk id say, odds stacked in favour of everything going smoothly... perhaps the risk is greater that if you don't buy now you will be paying a lot more when its signed off as a done deal.
my purchase @ 16p the other week don't look so daft either.
itsaduter, I wasn't telling people not to take their OO! As in the title of the post! Just that the purchase of VIY in advance of the EGM tomorrow was risky. Past the EGM, it's all clear. However, the market has spoken today and I'm sure it will all be fine. The EGM is normally a formality, but I'm cautious about these things. Post reverse t/o this share is super stuff and I'm pleased to be involved in something that's not just a good commercial proposition, but a great product for our wives, daughters and friends in the future (just for starters).
Guys.
26.92 now keep up.
gorillas - I mean guerillas - lol.
Come on
tightened right up now from 15% to 6% and still ticking up 26.92% ^
let's see the share price rise
tipped as below? spread tightening and up 23%
woohh,,what's triggered this!
Up she goes....!
Not long now
As a general rule of thumb we here at the world’s most infamous, libellous blog don’t usually cover stocks outside of the oil & gas/mining sectors. So it should be a surprise to learn that after slating SOFTWARE & COMPUTER SERVICES AIM listed Vialogy (VIY) shares when the “other lot” were in charge we are now or should I say ‘I have now increased my original token holding” and here’s why. The new improved Vialogy came back from restructuring/suspension a far healthier body politick, the tumour that was killing the Company has been excised. There is new life and where’s there’s life there is hope. Especially when Institutions have piled in en-mass because the new ‘cheeky chappies’ in charge have done exactly what they’ve promised to do here, before, a turnaround, making money for share-holders. The company rescuers are Adam Reynolds, David Evans and Stephen Little from Premaitha. A well-respected triumvirate! Suggest those that looking for a quick spin. Do their sums. The recent £6.5 million placing at 0.11p. was FOUR TIMES oversubscribed with a raft of institutions now on board. I never took part in that placing because I was too busy with other matters and no one approached me! But I have bought in at a significantly higher price. “Vialogy has conditionally acquired the entire issued share capital of Premaitha, which is a molecular diagnostic company. The consideration of £10.5 million is to be satisfied by the issue of 95,454,545 New Ordinary Shares at a price of 11 pence per share. The Company has raised £6.5 million (before expenses) by means of the Placing and intends to raise up to a further £0.7 million by means of the Open Offer. The net proceeds of the Placing and the Open Offer will be used to develop and commercialize the IONA® Test, a non-invasive pre-natal screening test for Down’s Syndrome developed by Premaitha, and for general working capital purposes. The Acquisition, if completed, is of sufficient size to constitute a reverse takeover under the AIM Rules and therefore is subject to the approval of shareholders at a General Meeting to be held at 11.00 a.m. on 3 July 2014 at the offices of Panmure Gordon (UK) Limited, One New Change, London EC4M 9AF” Premaitha is working on the final development and commercialisation of a non-invasive pre-natal screening test for Down’s syndrome developed by Premaitha. The market for this is very, very large. $4.2 billion. Once the consolidation and proposals go through basically a foregone conclusion Vialogy will have £8,000,000 million in cash. In order for Adam Reynolds to take his options package at 0.1p or 10p post consolidation Vialogy would have to have been trading at above 0.5p or 50p post consolidation for 30 consecutive days. That speaks volumes to me. If Reynolds believes he can do this then I know that the Board are rolling their sleev